Real-world analysis of treatments, healthcare costs, and overall survival among patients with metastatic non-small cell lung cancer by molecular biomarker testing approach

Cancer Treatment and Research Communications · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles